{"product_id":"tak-bcg-matrix","title":"(TAK) Takeda Pharmaceutical Company Limited BCG Matrix Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDownload Your Competitive Advantage\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Takeda Pharmaceutical Company Limited BCG Matrix is a ready-made tool for understanding how the company’s products or business units may fall into Stars, Cash Cows, Question Marks, and Dogs for strategy and portfolio analysis. The page already shows a real preview of the actual report content, so you can review what you’ll receive before buying. Purchase the full version to get the complete ready-to-use analysis instantly.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eStars\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEntyvio global IBD leader\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEntyvio is Takeda Pharmaceutical Company Limited’s flagship biologic for ulcerative colitis and Crohn’s disease, and it stays a Star because IBD affects over 7 million people worldwide. Takeda sells it in more than 70 countries, and the drug has kept strong global brand pull as biologic use keeps rising. That broad reach and durable demand make Entyvio Takeda’s key growth engine.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTakhzyro HAE prophylaxis leader\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTakhzyro stays a leading hereditary angioedema prophylaxis drug, with trials showing up to a 91% median reduction in attack rate on 300 mg every 2 weeks. HAE affects about 1 in 50,000 people, and better diagnosis is pushing more patients into preventive care. That makes Takhzyro a strong Star in a specialty market that is still expanding.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTakecab Japan P-CAB franchise\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTakecab Japan is a Star for Takeda Pharmaceutical Company Limited: it is a first-in-class potassium-competitive acid blocker and keeps a strong domestic share in acid-related disorders. In FY2025, the brand kept expanding through new uses, including reflux and H. pylori regimens, as physician adoption widened. High share plus continued growth keeps this franchise in the Star quadrant.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eAdcetris CD30 lymphoma standard\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAdcetris is still a core CD30 lymphoma brand for Takeda Pharmaceutical Company Limited, with use in Hodgkin lymphoma and systemic ALCL and ongoing demand in earlier-line and combination regimens. In Takeda Pharmaceutical Company Limited’s FY2024 results, Adcetris stayed a meaningful oncology contributor, supporting a high-share position in a niche market that still expands as treatment moves earlier. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCD30-positive lymphomas remain the core use case\u003c\/li\u003e\n\u003cli\u003eEarlier-line regimens keep the market active\u003c\/li\u003e\n\u003cli\u003eCombination use supports continued clinical demand\u003c\/li\u003e\n\u003cli\u003eHigh-share oncology asset for Takeda Pharmaceutical Company Limited\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eLivtencity CMV transplant therapy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eLivtencity is a first-in-class CMV treatment for transplant patients with refractory infection, and it fits a Star profile because demand is still early but rising. In the SOLSTICE study, 55.7% of patients hit the primary endpoint at week 8 versus 23.9% on the comparator, supporting share gains in a niche with clear unmet need.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFirst-in-class for refractory CMV\u003c\/li\u003e\n\u003cli\u003eWeek-8 response: 55.7% vs 23.9%\u003c\/li\u003e\n\u003cli\u003eAdoption is still early\u003c\/li\u003e\n\u003cli\u003eHigh growth, niche market\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTakeda’s Top Brands Deliver Strong Growth and Market Share\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eTakeda Pharmaceutical Company Limited’s Stars are Entyvio, Takhzyro, Takecab, Adcetris, and Livtencity. Entyvio leads with 7M+ IBD patients globally; Takhzyro cut HAE attack rates by up to 91%; Takecab kept growing in FY2025; Livtencity’s week-8 response was 55.7% vs 23.9%. These brands combine high share with clear growth.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eBrand\u003c\/th\u003e\n\u003cth\u003eKey data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eEntyvio\u003c\/td\u003e\n\u003ctd\u003e70+ countries; 7M+ IBD patients\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTakhzyro\u003c\/td\u003e\n\u003ctd\u003eUp to 91% attack-rate cut\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eTakeda’s BCG Matrix maps each business unit to guide invest, hold, or divest decisions across growth and profit pools.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eOne-page Takeda BCG Matrix for quick portfolio clarity and faster decisions\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eShows Takeda Pharmaceutical Company Limited reference sources, giving a credible trail that supports faster, better-informed decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eCash Cows\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGammagard Liquid\/Kiovig plasma IG\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGammagard Liquid and Kiovig are mature immunoglobulin brands with repeat dosing and a sticky patient base, so demand is steady rather than fast-growing. They fit Takeda Pharmaceutical Company Limited's cash cow bucket: low growth, strong share, and predictable cash flow.\u003c\/p\u003e\n\u003cp\u003eIn 2025, Takeda Pharmaceutical Company Limited's plasma-derived therapy portfolio remained a core earnings driver, with immunoglobulin use tied to chronic immune deficiency and neurology care.\u003c\/p\u003e\n\u003cp\u003eThat installed base matters: once patients start therapy, dosing often continues for years, which keeps revenue resilient even when unit growth stays modest.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHyqvia subcutaneous IG\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHyQvia supports chronic primary and secondary immunodeficiency patients on long-term subcutaneous Ig therapy, with infusions typically every 3-4 weeks. The franchise sits in a mature, retention-heavy market, so Takeda can harvest steady cash flow with limited promotional spend. That fits a classic Cash Cow in the BCG matrix, since repeat use and stable demand drive durable revenue.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCuvitru SCIG franchise\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCuvitru is a mature subcutaneous immunoglobulin franchise in Takeda Pharmaceutical Company Limited’s portfolio, serving a repeat-use specialty market where refills are steady and demand is predictable. In Takeda Pharmaceutical Company Limited’s FY2025, net sales were JPY 4,581.5 billion and adjusted operating profit was JPY 1,035.0 billion, showing strong cash generation. That makes Cuvitru a classic Cash Cow: low growth, dependable cash flow.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eAdvate hemophilia A factor\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAdvate is a long-standing recombinant factor VIII therapy for hemophilia A, and Takeda still benefits from an entrenched patient base in chronic prophylaxis. Even with slower growth versus newer treatments, it remains a high-margin, highly monetized brand in a disease that needs lifelong care. Takeda’s FY2025 net sales were ¥4.58 trillion, underscoring the scale that mature brands like Advate still support.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eInstalled base keeps volume sticky.\u003c\/li\u003e\n\u003cli\u003eGrowth is mature, not fast.\u003c\/li\u003e\n\u003cli\u003eHigh pricing supports cash generation.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eElaprase\/Replagal enzyme replacement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eElaprase and Replagal fit Takeda Pharmaceutical Company Limited’s cash cow bucket because both treat ultra-rare lysosomal storage diseases with lifelong, every-2-week infusions, which supports sticky, repeat demand and low churn. Elaprase is approved in more than 40 countries for Hunter syndrome, while Replagal is used in the EU and other markets for Fabry disease, where prevalence is only about 1 in 100,000 to 1 in 117,000. Limited competition and long treatment durations keep cash flow steady without heavy growth capex.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eUltra-rare patient pools\u003c\/li\u003e\n\u003cli\u003eChronic infusion demand\u003c\/li\u003e\n\u003cli\u003eLow competitive pressure\u003c\/li\u003e\n\u003cli\u003eStable, recurring revenue\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTakeda’s Cash Cows Power Steady Growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eTakeda Pharmaceutical Company Limited's cash cows are mature, repeat-use brands like Gammagard Liquid, HyQvia, Cuvitru, Advate, Elaprase, and Replagal. Their chronic or ultra-rare use keeps demand sticky and cash flow steady, while FY2025 Takeda Pharmaceutical Company Limited net sales reached JPY 4,581.5 billion and adjusted operating profit JPY 1,035.0 billion.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eBrand\u003c\/th\u003e\n\u003cth\u003eWhy it is a cash cow\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGammagard Liquid\u003c\/td\u003e\n\u003ctd\u003eRepeat Ig dosing\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHyQvia\u003c\/td\u003e\n\u003ctd\u003e3-4 week chronic use\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdvate\u003c\/td\u003e\n\u003ctd\u003eLifelong hemophilia care\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eGet Your Copy\u003c\/span\u003e\u003cbr\u003eTakeda Pharmaceutical Company Limited Reference Sources\u003c\/h2\u003e\n\u003cp\u003eYou're previewing the exact Takeda Pharmaceutical Company Limited BCG Matrix document you'll receive after purchase. What you see here is the same fully formatted file, with no demo content or placeholder pages. Once purchased, the report is instantly available for download and ready to use. It’s a clean, professional document designed for immediate business or strategy work.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eDogs\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNatpara discontinued\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNatpara was removed from normal commercial use after repeated safety and supply failures, including a 2019 U.S. recall and a long-running supply interruption. By FY2025, it had no meaningful growth profile and no material revenue contribution for Takeda Pharmaceutical Company Limited. It is a clear Dog in the BCG Matrix and a capital trap, with zero strategic upside and ongoing legacy burden.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAlofisel Europe exit\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAlofisel never built durable traction in Europe for complex Crohn’s-related fistulas, so Takeda ended commercialization after weak uptake and disappointing results. With a very small niche market and no growth engine, it fits the Dogs bucket. FY2025 Takeda net sales were ¥4.58 trillion, while Alofisel’s impact was immaterial.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExkivity low uptake\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eExkivity never gained broad adoption in EGFR exon 20 insertion NSCLC, and Takeda withdrew the U.S. product in 2023 after the confirmatory trial missed its key endpoint. With competing options and limited differentiation, the asset generated no meaningful sales by FY2025 and fits the Dog category. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eDexilant generic erosion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eDexilant is a classic \"Dog\" in Takeda Pharmaceutical Company Limited’s BCG Matrix: long patent erosion and generic entry have stripped pricing power, and the acid-suppression market is crowded with cheaper PPIs. That means low growth, fading volume, and shrinking share versus FY2025-era mature GI peers.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cp\u003eGeneric pressure caps margins.\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eVolume weakens in a crowded class.\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eShare declines as price falls.\u003c\/p\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eVyvanse US generic pressure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eVyvanse turned into a Dog after U.S. generic lisdexamfetamine entered in August 2023, triggering a fast sales slide for Takeda Pharmaceutical Company Limited. Even with ADHD still a large U.S. market, Vyvanse no longer shows growth, so the brand now acts like a low-share, low-growth asset. In FY2025, the business remained under heavy generic pressure and did not regain momentum.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eGeneric entry: August 2023\u003c\/li\u003e\n\u003cli\u003eUS share fell sharply\u003c\/li\u003e\n\u003cli\u003eFY2025 growth stayed weak\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTakeda’s Dogs: Low-Growth Legacy Assets With Little Value\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eTakeda Pharmaceutical Company Limited’s Dogs are legacy assets with weak or no FY2025 growth, shrinking share, and little capital value. Natpara, Alofisel, and Exkivity now contribute immaterial sales, while Dexilant and Vyvanse face severe erosion from patent loss and generic entry, making them low-return, low-growth holds.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003eFY2025 view\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNatpara\u003c\/td\u003e\n\u003ctd\u003eZero material sales\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAlofisel\u003c\/td\u003e\n\u003ctd\u003eImmaterial\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eExkivity\u003c\/td\u003e\n\u003ctd\u003eWithdrawn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDexilant\u003c\/td\u003e\n\u003ctd\u003eGeneric erosion\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eVyvanse\u003c\/td\u003e\n\u003ctd\u003ePost-generic decline\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eQuestion Marks\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFruzaqla 2025 mCRC launch\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eFruzaqla is a very recent metastatic colorectal cancer launch for Takeda Pharmaceutical Company Limited, so its BCG position is still a Question Mark. mCRC is a large, hard-fought market with crowded biologic and targeted rivals, and Takeda’s share is still in the build phase. It will need heavy launch spend and strong uptake in 2025 to move toward Star status.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eQinlock Deciphera 2024 asset\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eQinlock entered Takeda Pharmaceutical Company Limited through the 2024 Deciphera acquisition, a deal valued at about $2.4 billion in equity. In Deciphera’s 2024 results, Qinlock net product sales were $139.4 million, up 27% year over year, but it still serves a niche GIST market. The asset has growth room, yet its share is still being built, so it fits as a question mark, not a market leader.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAlunbrig ALK NSCLC challenger\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAlunbrig remains a challenger in ALK-positive NSCLC, a class that keeps expanding as more patients are diagnosed earlier and treated longer. Takeda still trails bigger rivals in share, while competitors like Alecensa, Xalkori and Lorbrena keep pressure high. In Takeda’s FY2025 results, Alunbrig still needed more uptake and broader label reach to move out of Question Mark territory.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eAdynovate\/Adynovi factor VIII\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAdynovate and Adynovi are in Takeda Pharmaceutical Company Limited’s Question Mark zone: hemophilia B and A treatment still has room, but non-factor drugs and gene therapies are taking share. Takeda has not shown a dominant, cash-cow level position here, so growth depends on faster uptake.\u003c\/p\u003e\n\u003cp\u003eIn 2025, the hemophilia class kept shifting toward longer-acting and one-time options, which makes factor VIII products more vulnerable. That means Adynovate\/Adynovi can still sell, but the brand needs stronger prescription growth to avoid drifting into a weaker BCG position.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eGrowth exists, but share is not dominant\u003c\/li\u003e\n\u003cli\u003eNon-factor and gene therapy pressure is rising\u003c\/li\u003e\n\u003cli\u003eNeeds better adoption to stay relevant\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eGattex\/Revestive SBS growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGattex\/Revestive targets short bowel syndrome, a rare niche that can expand as diagnosis and treatment rates rise; SBS is still underrecognized, so volume can grow from a small base.\u003c\/p\u003e\n\u003cp\u003eTakeda’s share is limited, and with no clear scale edge, the asset fits a 2025 question mark: high upside if penetration improves, but not yet a market leader.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRare, underdiagnosed SBS supports growth\u003c\/li\u003e\n\u003cli\u003eShare remains limited versus potential\u003c\/li\u003e\n\u003cli\u003eQuestion mark: growth possible, not proven\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTakeda’s Question Marks Need Faster Growth to Become Stars\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eTakeda Pharmaceutical Company Limited’s Question Marks are newer or niche assets with growth upside, but none yet hold clear market leadership. Fruzaqla and Qinlock are still scaling, while Alunbrig, Adynovate\/Adynovi, and Gattex\/Revestive face tougher share battles in 2025. They need faster uptake to move toward Star status.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003e2025 signal\u003c\/th\u003e\n\u003cth\u003eBCG fit\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eFruzaqla\u003c\/td\u003e\n\u003ctd\u003eNew mCRC launch\u003c\/td\u003e\n\u003ctd\u003eQuestion Mark\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQinlock\u003c\/td\u003e\n\u003ctd\u003e$139.4M sales, +27%\u003c\/td\u003e\n\u003ctd\u003eQuestion Mark\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAlunbrig\u003c\/td\u003e\n\u003ctd\u003eStill trails rivals\u003c\/td\u003e\n\u003ctd\u003eQuestion Mark\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57235115999497,"sku":"tak-bcg-matrix","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/tak-bcg-matrix.webp?v=1785733099","url":"https:\/\/dcfanalyst.com\/products\/tak-bcg-matrix","provider":"DCF Analyst","version":"1.0","type":"link"}